Signal peptides
AssigneeImperial College Innovations Limited
InventorsJack HICKMOTT, Eric ALTON, Uta GRIESENBACH, Possawee PRASERTSUK
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic acid cassettes for gene therapy, particularly to nucleic acid cassettes encoding therapeutic proteins in combination with exogenous signal peptides. The invention further relates to viral and non-viral vectors comprising such nucleic acid cassettes, and the use of such nucleic acid cassettes and vectors to increase expression of therapeutic proteins by airway cells.
Claims26
A nucleic acid cassette comprising:
- (a) a nucleic acid sequence encoding an exogenous signal peptide;
- and
- (b) a nucleic acid sequence encoding a therapeutic protein;
- wherein the exogenous signal peptide (i) increases secretion of the therapeutic protein from airway cells and/or (ii) increases insertion of the therapeutic protein into the cell membrane of airway cells.
The nucleic acid cassette of any one of the preceding claims, wherein the exogenous signal peptide comprises or consists of:
- (a) an amino acid sequence having at least 90% identity to an amino acid selected from the group consisting of:
- SEQ ID NOs:
- 1-12;
- or
- (b) an amino acid sequence selected from the group consisting of:
- SEQ ID NOs:
- 1-12.
The nucleic acid cassette of any one of the preceding claims, wherein the nucleic acid sequence encoding the exogenous signal peptide is 5′ of the nucleic acid sequence encoding the therapeutic protein.
The nucleic acid cassette of any one of the preceding claims, which further comprises a promoter configured to express the nucleic acid sequence encoding the exogenous signal peptide and the therapeutic protein.
The nucleic acid cassette of any one of the preceding claims further comprising:
- (a) a translation initiation sequence;
- and/or
- (b) an internal ribosome entry sequence (IRES).
The nucleic acid cassette of any one of the preceding claims, wherein the therapeutic protein is:
- (a) a secreted therapeutic protein selected from:
- AAT, Factor VIII, Surfactant Protein B (SP-B), Factor VII, Factor IX, Factor X, Factor XI, van Willebrand Factor, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Surfactant Protein C (SP-C), decorin, an anti-inflammatory protein (e.g. IL-10 or TGFβ) or monoclonal antibody, an anti-inflammatory decoy, or a monoclonal antibody against an infectious agent;
- or
- (b) CFTR, TRIM72, CSF2RA, CSF2RB or ATP-binding cassette sub-family A member 3 (ABCA3).
The nucleic acid cassette of any one of the preceding claims, wherein the airway cells are:
- (a) lung cells;
- and/or
- (b) selected from epithelial cells, basal cells, submucosal gland duct cells, club cells, neuroendocrine cells, bronchoalveolar stem cells, submucosal acinar cells, ionocytes, type I pneumocytes and/or type II pneumocytes.
A gene therapy vector, comprising a nucleic acid cassette as defined in any one of the preceding claims.
Dependencies are inferred from the claim text.